Jonathan Bass, PhD

Patent Agent

Contact Me

Services & Specializations

Admissions

US Patent & Trademark Office

Languages

Spanish

Address

200 Spectrum Center Drive, Suite 1650, Irvine, CA 92618

Office Tel.

619.515.3256

VCard

Overview

Jonathan is a registered U.S. patent agent with significant experience drafting and prosecuting patent applications and managing complex patent portfolios in the pharmaceutical and biotechnology industries. His practice includes U.S. and international prosecution, reissue applications, USPTO appeal briefs, EPO opposition proceedings, freedom to operate and patentability analyses, and intellectual property due diligence, as well as license and collaboration agreement analysis. Jonathan regularly advises on portfolio strategy to maximize cost efficiency and patent term.

Jonathan has a PhD in Chemistry and his technical background spans small molecule pharmaceuticals, therapeutic antibodies, gene therapy, pharmaceutical formulations and solid forms, medical devices, and a broad range of chemistry disciplines, including organic, medicinal, organometallic, polymer, and materials chemistry. He previously worked in-house at AbbVie and Allergan.

Directed and managed global patent strategy for a gene therapy collaboration portfolio comprising more than 250 patents and applications, identifying opportunities to extend exclusivity and optimize patent term.
Advised commercial and research teams on intellectual property strategy for marketed and clinical stage pharmaceutical assets, serving as the IP lead on cross-functional project teams.
Successfully defended a European patent opposition, preventing revocation of a patent covering a commercial small molecule ocular implant.
Prosecuted and oversaw out licensed patent portfolios covering clinical assets, including portfolios tied to the sale of a licensee to a large pharmaceutical company.
Managed a global portfolio of more than 2,500 patents and applications across more than 30 countries relating to early stage and commercial small molecule programs.
Led management of a worldwide collaboration portfolio of more than 150 patents and applications and served as primary IP liaison with the collaboration partner.
Drafted and prosecuted U.S. and foreign patent applications, including reissue applications and PTAB appeals, conducting examiner interviews and securing hundreds of patent allowances worldwide.

PhD (Chemistry), University of California, Irvine
BS (Chemistry), The University of North Carolina at Chapel Hill

Co-author. “Single-Molecule Imaging of Platinum Ligand Exchange Reaction Reveals Reactivity Distribution,” Journal of the American Chemical Society, 132(43), 15167–15169, 2010.
Co-author. “FXR Agonist Activity of Conformationally Constrained Analogs of GW 4064,” Bioorganic & Medicinal Chemistry Letters, 19(16), 4733–4739, 2009.
Co-author. “Substituted Isoxazole Analogs of Farnesoid X Receptor (FXR) Agonist GW 4064,” Bioorganic & Medicinal Chemistry Letters, 19(11), 2969–2973, 2009.
Co-author. “Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Naphthoic Acid-Based Analogs of GW 4064,” Bioorganic & Medicinal Chemistry Letters, 18(15), 4339–4343, 2008.
Co-author. “Toward the Single-Molecule Investigation of Organometallic Reaction Mechanisms: Single-Molecule Imaging of Fluorophore-Tagged Palladium(II) Complexes,” Organometallics, 27(10), 2172–2175, 2008.
Co-author. “2-Cyano-4-fluoro-1-thiovalylpyrrolidine Analogues as Potent Inhibitors of DPP-IV,” Bioorganic & Medicinal Chemistry Letters, 15(23), 5257–5261, 2005.

‌

‌
‌

‌

‌
‌
‌
‌

‌
‌

‌
‌
‌

‌
‌

Representative Matters

Directed and managed global patent strategy for a gene therapy collaboration portfolio comprising more than 250 patents and applications, identifying opportunities to extend exclusivity and optimize patent term.
Advised commercial and research teams on intellectual property strategy for marketed and clinical stage pharmaceutical assets, serving as the IP lead on cross-functional project teams.
Successfully defended a European patent opposition, preventing revocation of a patent covering a commercial small molecule ocular implant.
Prosecuted and oversaw out licensed patent portfolios covering clinical assets, including portfolios tied to the sale of a licensee to a large pharmaceutical company.
Managed a global portfolio of more than 2,500 patents and applications across more than 30 countries relating to early stage and commercial small molecule programs.
Led management of a worldwide collaboration portfolio of more than 150 patents and applications and served as primary IP liaison with the collaboration partner.
Drafted and prosecuted U.S. and foreign patent applications, including reissue applications and PTAB appeals, conducting examiner interviews and securing hundreds of patent allowances worldwide.

Thought Leadership

Co-author. “Single-Molecule Imaging of Platinum Ligand Exchange Reaction Reveals Reactivity Distribution,” Journal of the American Chemical Society, 132(43), 15167–15169, 2010.
Co-author. “FXR Agonist Activity of Conformationally Constrained Analogs of GW 4064,” Bioorganic & Medicinal Chemistry Letters, 19(16), 4733–4739, 2009.
Co-author. “Substituted Isoxazole Analogs of Farnesoid X Receptor (FXR) Agonist GW 4064,” Bioorganic & Medicinal Chemistry Letters, 19(11), 2969–2973, 2009.
Co-author. “Conformationally Constrained Farnesoid X Receptor (FXR) Agonists: Naphthoic Acid-Based Analogs of GW 4064,” Bioorganic & Medicinal Chemistry Letters, 18(15), 4339–4343, 2008.
Co-author. “Toward the Single-Molecule Investigation of Organometallic Reaction Mechanisms: Single-Molecule Imaging of Fluorophore-Tagged Palladium(II) Complexes,” Organometallics, 27(10), 2172–2175, 2008.
Co-author. “2-Cyano-4-fluoro-1-thiovalylpyrrolidine Analogues as Potent Inhibitors of DPP-IV,” Bioorganic & Medicinal Chemistry Letters, 15(23), 5257–5261, 2005.

Services & Specializations

Admissions

Languages

Address

Office Tel.

Overview

Representative Matters

Education

Thought Leadership

Services & Specializations

Admissions

Languages

Address

Office Tel.

Overview

Representative Matters

Education

Thought Leadership